Steven Cohen’s Contineum Therapeutics CTNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$316K Sell
23,550
-2,229
-9% -$33.2K ﹤0.01% 3326
2026
Q2
$423K Sell
25,779
-59,112
-70% -$775K ﹤0.01% 3244
2026
Q1
$1.11M Sell
84,891
-674,336
-89% -$9.04M ﹤0.01% 2707
2025
Q4
$8.68M Buy
759,227
+391,582
+107% +$4.47M 0.01% 1445
2025
Q3
$4.32M Sell
367,645
-20,994
-5% -$169K 0.01% 1121
2025
Q2
$1.54M Buy
+388,639
New +$1.69M ﹤0.01% 1410

Other funds holding CTNM

Steven Cohen's CTNM Position: Q3 2026 in Review

Steven Cohen reduced its Contineum Therapeutics (CTNM) stake by 8.6% in Q3 2026, selling an estimated $33.2K and leaving 23,550 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #3326.

Steven Cohen first reported a position in CTNM in Q2 2025 and has held it in 6 quarters since. The position peaked at $8.68M in Q4 2025. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Steven Cohen held 23,550 shares of Contineum Therapeutics worth $316K as of Q3 2026.
  • Steven Cohen sold 2,229 Contineum Therapeutics shares in Q3 2026, an estimated $33.2K.
  • Contineum Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q3 2026, its #3326 holding.
  • Steven Cohen first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Steven Cohen's Contineum Therapeutics position peaked at $8.68M in Q4 2025.
  • 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.